Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting NR2F6
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Ophthalmic, Rectal, Vaginal, Sublingual, Buccal, Transdermal, Intradermal, Intrathecal, Intraarticular, Intratumoral, Intralesional, Intraperitoneal, Intra-arterial, Epidural, Parenteral, Implant
01
Overview
siRNA targeting NR2F6 is a small interfering RNA (siRNA) research reagent designed to silence or inhibit the expression of the NR2F6 (Nuclear Receptor Subfamily 2 Group F Member 6) gene. NR2F6 is an orphan nuclear receptor that acts as an intracellular immune checkpoint in T cells, and its suppression has been shown to enhance anti-tumor immune responses, particularly when combined with PD-1/PD-L1 blockade. Additionally, silencing NR2F6 has been investigated for its direct inhibitory effects on tumor cell proliferation in various cancers, including breast cancer, lung cancer, and neuroblastoma. This compound is primarily utilized as a research tool and is available from multiple laboratory reagent suppliers.
- Other names
- NR2F6 siRNANR-2F6 siRNANR 2F6 siRNAsiRNA targeting nuclear receptor subfamily 2 group F member 6
02
Targets
NR2F6 (Nuclear receptor subfamily 2 group F member 6)
Beyond the preview
Go deeper on siRNA targeting NR2F6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting NR2F6.